Back to top
more

Vanda Pharmaceuticals (VNDA)

(Delayed Data from NSDQ)

$5.40 USD

5.40
885,375

-0.24 (-4.26%)

Updated Aug 2, 2024 04:00 PM ET

After-Market: $5.40 0.00 (0.00%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.03%
2Buy17.70%
3Hold9.37%
4Sell5.03%
5Strong Sell2.48%
S&P50011.19%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

4-Sell of 5       4  

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value F Growth A Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 36% (91 out of 251)

Industry: Medical - Biomedical and Genetics

Better trading starts here.

Zacks News

Earnings Preview: Vanda Pharmaceuticals (VNDA) Q1 Earnings Expected to Decline

Vanda (VNDA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Vanda Pharmaceuticals (VNDA) Tops Q4 Earnings and Revenue Estimates

Vanda (VNDA) delivered earnings and revenue surprises of 100.00% and 3.33%, respectively, for the quarter ended December 2018. Do the numbers hold clues to what lies ahead for the stock?

Vanda (VNDA) Q4 Earnings: What's in Store for the Stock

On Vanda's (VNDA) fourth-quarter 2018 conference call, investor focus will be on the sales figure of its two marketed drugs, Hetlioz and Fanapt.

Amgen's Postmenopausal Osteoporosis Drug Gets FDA Panel Nod

Amgen (AMGN) gets positive vote from a FDA panel for osteoporosis candidate, Evenity.

Zacks.com featured highlights include: Inseego, Meet, Vanda, Crocs and Bluerock Residential

Zacks.com featured highlights include: Inseego, Meet, Vanda, Crocs and Bluerock Residential

5 Stocks With Recent Price Strength Despite Volatile Market

Investors target stocks that have been on a bullish run lately. Actually, stocks seeing price strength have a high chance of carrying the momentum forward.

ASLAN's Varlitinib Fails to Meet Endpoint in Phase II Study

ASLAN's (ASLN) varlitinib is unable to show any statistical significance for the primary endpoint in a phase II study with regard to first-line treatment of advanced or metastatic gastric cancer.

Acorda (ACOR) Plans to Launch Inbrija in Q1: What to Expect

Acorda (ACOR) aims to unveil its newly FDA-approved Parkinson's disease drug, Inbrija, in the first quarter of 2019. The company's pipeline looks strong.

Amgen's Osteoporosis Candidate Evenity Gets Approval in Japan

Amgen (AMGN) gets approval in Japan for osteoporosis candidate, Evenity.

Emergent (EBS) Up on '19 View, Posts Preliminary '18 Results

Emergent (EBS) provides preliminary results for 2018 and guidance for 2019. The results exceed estimates.

Emergent (EBS) CEO Abdun Nabi to Retire, Kramer to Succeed

Emergent (EBS) names Robert G. Kramer, Sr. as its next chief executive officer, who will assume office from Apr 1, 2019 onward. He will succeed the incumbent CEO Daniel J. Abdun-Nabi.

Sejuti Banerjea headshot

Bull or Bear: Your Investment Strategy for 2019

Whether you're a bull or a bear, it may be a good idea to go defensive about now.

Vertex Joins Forces With Arbor to Build Gene-Editing Therapies

Vertex (VRTX) inks a collaboration deal with small biotech entity Arbor to discover novel proteins for progressing discovery of gene-editing therapies to tackle serious ailments.

Emergent (EBS) Files Application for Emergency Use of NuThrax

Emergent (EBS) submits an application to the FDA for the emergency use of its anthrax vaccine candidate, NuThrax.

Madhura Bhattacharyya headshot

Ring in 2019 With These 7 Solid Growth Stocks in Your Kitty

Let's take a look at seven growth stocks that are poised to offer impressive returns in 2019.

Four Biotech Stocks That Popped More Than 50% in 2018

The biotech sector has failed to impress the investors in 2018 which has underperformed the broader S&P 500 market. However, we provide four biotech companies which performed well in this scenario.

The Zacks Analyst Blog Highlights: Vanda Pharmaceuticals, Penumbra, G-III Apparel and General Finance

The Zacks Analyst Blog Highlights: Vanda Pharmaceuticals, Penumbra, G-III Apparel and General Finance

The Zacks Analyst Blog Highlights: Vanda Pharmaceuticals, Penumbra, G-III Apparel and General Finance

The Zacks Analyst Blog Highlights: Vanda Pharmaceuticals, Penumbra, G-III Apparel and General Finance

The Zacks Analyst Blog Highlights: Vanda Pharmaceuticals, Penumbra, G-III Apparel and General Finance

The Zacks Analyst Blog Highlights: Vanda Pharmaceuticals, Penumbra, G-III Apparel and General Finance

Ankita Gupta headshot

4 Stocks That Had Massive Earnings Surprises in 2018

Given the market volatility, let's take a look at four stocks that survived the onslaught and even surpassed market expectations.

Inovio (INO) to Receive Milestone Payment From AstraZeneca

Inovio (INO) to receive an undeclared milestone amount from AstraZeneca following the initiation of dosing in a phase II combo inspection of the latter's MEDI0457 for treating HPV-related cancers.

Amgen's BiTE Immunotherapies Show Promise in Early Studies

Amgen's (AMGN) BiTE immunotherapy candidates, namely AMG 420 and AMG 330 show positive results in early-stage studies. AMG 420 gets a fast track designation from the FDA

Company News For Dec 4, 2018

Companies In The News Are: TSRO,GSK,TRCO,NXST,VNDA,GBT

FDA Committee to Review Amgen's (AMGN) Osteoporosis Candidate

The FDA's BRUDAC committee will review Amgen (AMGN) and its European partner UCB's BLA for Evenity so that the candidate gets approved for treating osteoporosis in postmenopausal women.

Zacks.com highlights: Vericel, Mitek, Vanda Pharmaceuticals, Mosaic and Spirit Airlines

Zacks.com highlights: Vericel, Mitek, Vanda Pharmaceuticals, Mosaic and Spirit Airlines